Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT03356483
PHASE1

Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.

Sponsor: Yale University

View on ClinicalTrials.gov

Summary

This study aims to investigate the effects of oral psilocybin on OCD symptomatology and provide the first evidence of the neural mechanism that may mediate psilocybin's purported therapeutic effects on OCD.

Official title: Psilocybin Treatment in Obsessive-Compulsive Disorder: a Preliminary Efficacy Study and Exploratory Investigation of Neural Correlates.

Key Details

Gender

All

Age Range

21 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

28

Start Date

2018-11-13

Completion Date

2024-07-25

Last Updated

2026-10-16

Healthy Volunteers

No

Interventions

DRUG

Psilocybin (0.25mg/kg)

Psilocybin is a naturally occurring hallucinogenic ingredient found in some varieties of mushrooms that can be produced synthetically. It is considered to be a serotonergic psychedelic.

DRUG

Niacin (250mg)

A medication used to treat high cholesterol, triglyceride levels, and niacin deficiency.

Locations (1)

Enact Research Collaborative

New Haven, Connecticut, United States